 azathioprin prednison treatment idiopath pulmonari fibrosi prospect double-blind placebo-control clinic trial twenty-seven patient idiopath pulmonari fibrosi ipf ipf prospect double-blind placebo-control studi therapeut effect combin prednisone/azathioprin prednison placebo prednison mg/kg/day mg/day first wk biweekli taper mainten dose mg/day azathioprin daili dose mg/kg mg/day patient use azathioprin well side effect chang lung function yr alveolar-arteri oxygen differ a-a fvc singl breath diffus capac carbon monoxid dlcosb azathioprine/prednison group prednison group none comparison signific six patient plu azathioprin follow-up period patient plu placebo cox model surviv analysi nonsignific larg surviv advantag azathioprine/prednison hazard ratio confid interv age surviv advantag azathioprine/prednison signific hazard ratio confid interv larg sampl approxim random test prednison azathioprin safe effect regimen treatment ipf